Biophytis today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily engaged in the manufacturing and distribution of healthcare products.
Biophytis announces that it took part in NVIDIA’s world-renowned GTC conference, the ultimate global stage for AI innovation. Held from March 16 to 19, 2026, Biophytis participated at NVIDIA GTC, widely recognized as one of the world’s leading conferences dedicated to artificial intelligence and accelerated computing. The event brought together more than 25,000 in-person attendees…
Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research Next-generation drug candidates against sarcopenia Next generation drug candidates for dry age-related macular degeneration (AMD) Paris (France), Cambridge…
Biophytis SA today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription rights of the Company’s existing shareholders in favor of several institutional investors, for a total gross amount of €2,015,000 (the “Issue”).
Biophytis SA announces several amendments to the bond financing announced on August 5, 2025, in joint agreement with Hexagon Capital Fund.
Biophytis announces the signing of a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding Ltd, designed to accelerate the development and commercialization of BIO101 in sarcopenia in Asian markets.
Biophytis announces its participation in two leading healthcare and investment events in January 2026.
All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 31% of the shareholders present or…
Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half of 2025 marks a decisive milestone in the execution of our strategy. With the signing of a memorandum of understanding to create a joint venture…
BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong Kong Injection of US$20 million by the consortium of Asian investors Start of clinical operations in early 2026 A landmark Memorandum of Understanding (MoU) has…
Biophytis to Participate in Four Key Events in Q4 2025 Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy: CF&B Midcap Events Paris, September 30 – October 1, 2025 Geneva, December 10, 2025 BIO-Europe (Vienna, November 3–5, 2025) SCWD Annual Conference (Rome, December 11–13, 2025) In Paris…
Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial of BIO101 in muscle wasting associated with obesity. The Company via its subsidiary in Brazil has secured funding support from EMBRAPII (Empresa Brasileira de Pesquisa e…
Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial of BIO101, targeting age related sarcopenia. This trial is designed to be the first phase 3 ever conducted in sarcopenia, reflecting the medical need in…
Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Biophytis announces that the European Medicines Agency (EMA) has issued a favorable outcome on Part I of its Clinical Trial Application (CTA) for the initiation of a Phase 2 clinical trial of BIO101 (20-hydroxyecdysone) in patients suffering from muscle wasting associated with…
Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 2 OBA trial of BIO101, targeting muscle wasting associated with obesity. This new program underscores Biophytis’s ambition to broaden the potential of its lead candidate BIO101 into high-prevalence…
Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis announced that both Part I (European Medicines Agency scientific review) and Part II (Belgian national ethical assessment) of its Clinical Trial Application (CTA) for a Phase 3 study in sarcopenia have been successfully reviewed and accepted. With these approvals, Biophytis…
Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Biophytis announces the establishment of a non-dilutive bond financing line for a maximum amount of €1 million with Hexagon Capital Fund, with an initial subscription of €100,000. Fullscreen Mode
Biophytis Joins Silver Innov’, an Incubator Dedicated to the Silver Economy Biophytis is relocating to Silver Innov, an incubator and business center specialized in innovation, healthcare, and aging. This move represents a key milestone in Biophytis’ strategic roadmap, reinforcing its presence within an ecosystem dedicated to the silver economy, healthy aging, and biopharmaceutical innovation. As…
Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artificial intelligence solutions for life sciences. The collaboration aims to accelerate the discovery and development…
Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced its financial results for the…
Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025 Biophytis announces its participation in the 7th edition of the World Aging & Rejuvenation Conference (ARC 2025), to be held in Vienna, Austria, from July 9 to 10, 2025. As part of this internationally renowned event dedicated to aging and…
Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized obesity management by enabling significant…
Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode
Biophytis announces the temporary suspension of the trading of its shares Biophytis announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the accounts by the statutory auditors,…
Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces its participation to the BIO International Convention, which will take place this year in Boston, USA, from June 16 to 19, 2025. Edouard Bieth, Chief Strategy Officer at Biophytis, will be present and will take part in numerous meetings…
Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. The Company requires additional time to complete the audit and certification of its accounts. As a result, Biophytis will publish its 2024 annual…
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis announced its active participation at the 32nd European Congress on Obesity (ECO 2025), held from May 11 to 14 in Malaga, Spain. During this premier international event, which brings together leading experts, clinicians, researchers, and industry stakeholders to discuss the latest advances…
Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its efforts on the related discussions…
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients’…
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025. Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th…
Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Biophytis announces today the settlement and delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium), carried out through the issuance,…
Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit; Gross…
Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility. New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model. Biophytis announces new preclinical…
Biophytis revolutionizes sarcopenia Biophytis is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the key reference journal for research on sarcopenia. Key BIO101 Attributes from the SARA INT Trail include: Promising Efficacy: BIO101 350mg bid demonstrates a clinically meaningful…
Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse. The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual…
Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development program for the treatment of obesity, Strategic licensing agreement signed with…
Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction Biophytis announces today that the listing of its ordinary shares and share warrants on the Euronext Growth market, and its American Depositary Shares (ADS) on the OTC market, will be temporarily suspended as from the…
Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference Will participate also in the following events: Sachs Conference – BioPharma Obesity Innovation Forum The BIO@JPM Week Conference Biophytis announces its participation in the inaugural BioPharma Obesity Innovation Forum (#Sachs_BOIF) on January 11, 2025, in San Francisco, as well as in the…
Biophytis showcased the OBA program in obesity at the 17th SCWD international congress Biophytis took part in the 17th international SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) congress, a flagship event bringing together experts from around the world to share innovations on sarcopenia, cachexia and muscle wasting including weight loss induced muscle disorders. At…
You can find the video of the Obesity Investor Call and the presentation of the various speakers by clicking on this link:
Biophytis its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8, 2024, in Washington, D.C. As part of the congress, Biophytis will host an Obesity Investor Call on the topic: “GLP-1 RA weight loss therapy-induced muscle loss: A medical need to…
During the recent European Respiratory Society (ERS) conference held in Vienna, Prof. Capucine Morelot-Panzini, Head of Pneumonology at Pitié-Salpêtrière Hospital and Professor at Sorbonne University, presented the positive results of the COVA phase 2/3 trial on 20-hydroxyecdysone (BIO101) for the treatment of hospitalized severe COVID-19 patients. Her presentation highlighted a statistically significant reduction in the…
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Biophytis announces the deployment of its partnership strategy in Asia. To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These…
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26,…
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with…
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million Biophytis announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and…
Biophytis extends its contract with Atlas to secure financing for its business activities Biophytis announces the extension of its bond financing agreement with Atlas, a specialized investment fund based in New York (USA), in order to secure financing for its business activities, in particular the launch of its clinical programs OBA in obesity and MYODA…
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and speciality markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and speciality products, has produced the first GMP-compliant batch of BIO101 (20-hydroxyecdysone) at its plant in…
Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). Fullscreen Mode
Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université – Amphi Herpin – 4 Place Jussieu, 75005 Paris. The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des…
Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and…
Biophytis is deploying its partnership strategy in obesity Biophytis today the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with the Company being fully committed to drive groundbreaking scientific and technological advances that have the potential…
Biophytis Announces Transfer of ADSs to OTC Market ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as its primary trading market Biophytis annouced that on April 24, 2024, the Company received formal…
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Biophytis annouces that it will change the ratio of its American Depositary Shares (the “ADSs”) to Biophytis ordinary shares (the “Shares”) from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the “Ratio Change”). The effective date of the Ratio Change (the…
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Biophytis announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity. This Scientific Advisory Board will be…
Biophytis files a patent application and strengthens its intellectual property in obesity Biophytis announces the filing of a patent application in the treatment of obesity, a new indication in which the Company has positioned itself with the announcement of its phase 2 OBA clinical trial. This new patent application, which is expected to be granted…
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Biophytis announces that it is launching a new clinical development program named OBA, with BIO101 (20- hydroxyecdysone) as a potential treatment for obesity in combination with…
Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. “In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development…
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a…
Biophytis presented its phase 3 protocol in the treatment of sarcopenia Biophytis presented its phase 3 protocol aimed at demonstrating the potential of Ruvembri™ (20-hydroxyecdysone) in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR), held from March 20 to 22, 2024 in Albuquerque, NM, USA. The SARA-INT phase 2…
Combined General Meeting of April 2, 2024 Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, will hold…
Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth Biophytis announces that it has decided to implement a reverse stock split, with effect from April 2 2024, on the basis of 1 new share for every 400 held. Fullscreen Mode
Biophytis presented the potential of Ruvembri™ in the treatment of Duchenne Muscular Dystrophy Biophytis presented the results of its recent clinical trials with Ruvembri™ at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA. Administered orally, Ruvembri™ activates the MAS receptor, stimulating respiratory and motor…
“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas Veillet, CEO and co- founder of the company, together with René Lafont, Professor Emeritus at Sorbonne University and co- founder of Biophytis, and Jean Mariani, Professor and Director of the…
Following the recent publication of the results of the COVA clinical trial (phase 2-3) in eClinicalMedicine (The Lancet), Biophytis organized a webcast to present the Group’s ambitions in the treatment of respiratory viral infections such as Covid-19 and influenza. https://vimeo.com/905775870
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract Biophytis announces the drawing of a new tranche of Bonds Redeemable in Cash and New and Existing Shares (ORNANE) under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States). Fullscreen Mode
Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure Biophytis announces the signing of a new partnership with the University of Liège to carry out a range of preclinical research projects, particularly in the treatment of respiratory failure caused by the flu virus Influenza. Under…
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board Biophytis announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board. Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development…
Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million Biophytis announces the successful completion of its capital increase with shareholders’ pre-emptive subscription rights (DPS) through the issue of shares with redeemable share warrants (ABSAR), for an amount, including issue premium, of approximately €1.96 million (the “Capital Increase”). Stanislas…
Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil Biophytis announces the signature of a partnership with Innovation Solutions Pharma, a company specializing in support for clinical development and drug registration operations in South America, with a view to accelerate market access for Sarconeos (BIO101) in…
Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel Biophytis announces that it has received a notice of delisting from Nasdaq. The staff of the Listing Qualifications Department has determined that the Company’s securities have not regained compliance with the minimum $2,500,000 stockholders’ equity requirement…
Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap Public offering of ABSARs: new shares with redeemable share subscription warrants (BSARs) Subscription price: €0.0093 per new share each with a subscription warrant Subscription ratio: 3 ABSARs for 8 existing shares Trading…
Next week, our CBO, Edouard Bieth, will be attending the Pharma Partnering Summit in Boston, US! Hope to meet you there to learn more about how Biophytis is contributing to the future of biotechnology and discuss potential partnership opportunities. To arrange a one-to-one meeting, please send a message directly to the following email address: edouard.bieth@biophytis.com…
Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA) Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first,…
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) Biophytis and Skyepharma, a French pharmaceutical company specializing in the formulation, development and production of pharmaceutical products, announce the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, with a view to…
Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Biophytis announced that it has received a response from the French National Authority for Health (HAS) to its request for Early Access Authorization in France for patients suffering from severe forms of COVID-19 and provides…
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer Biophytis announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “Over the past two years, Biophytis has made significant progress…
During the 25th annual H.C. Wainwright Global Investment Conference, Biophytis’ CEO Stanislas Veillet presented the company, its ambitions and the latest progress it made on its various projets. A replay will be available for 90 days at the following link: https://journey.ct.events/view/1037e68b-3f79-4b25-9a15-27affba4d7c4 Watch here
Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia Biophytis announced that it has received FDA (Food and Drug Administration) authorization to launch its SARA-31 study in the US, the first ever phase 3 study in sarcopenia. This authorization complements the positive opinion obtained this summer from the Belgian authorities to…
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York Biophytis announces that its CEO, Stanislas Veillet, will participate and hold a presentation at the “H.C. Wainwright 25th Annual Global Investment Conference”, which takes place from September 11 to 13, 2023 in New York. The presentation will be available post-meeting on…
Biophytis announces next regulatory steps in Europe and the United States for its COVA project Biophytis announced that it has received feedback from the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) enabling it to plan the next regulatory steps for its COVA project dedicated to the development of Sarconeos (BIO101) for…
Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe Biophytis announced that it has received a positive opinion from Belgian authorities to conduct its SARA-31 program, which will be the first phase 3 study ever launched in sarcopenia. The launch of the Phase 3 program follows the promising results…
Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19 Biophytis announced that it has filed for a pre-submission meeting request with the Food and Drug Administration (FDA) to discuss filing for Emergency Use Authorization (EUA) in the United States for Sarconeos (BIO101)…
Biophytis Announces $3.8 Million Registered Direct Offering Fullscreen Mode
Biophytis and SEQENS sign a partnership to produce Sarconeos Biophytis, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases and SEQENS, integrated global player in solutions and ingredients for the pharmaceutical and specialty…
Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress Biophytis announces that it is taking part in the 16th SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) international congress, a flagship event bringing together experts from all over the world to share thoughts, research and innovations on sarcopenia,…
Results of the annual general meeting on june 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting. Thanks to the mobilization of shareholders, the AGM could be…
Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June Biophytis announces it will participate at the Biotechnology Innovation Organization (BIO) International Convention to be held in Boston from the 5th to the 8th of June 2023, alongside thousands of world leaders in biotechnology and the pharmaceutical…
Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Biophytis announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation (EAA) in France with the French National Authority…
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference Biophytis announces that it presented the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the American Thoracic Society International Conference (ATS 2023) that was held in Washington DC between the 19th and…
Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia Biophytis announced that it has submitted the application for Clinical Trial Authorization (CTA) to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA (European Medicines Agency). The launch of the Phase 3…
Successful capital increase for Biophytis with €2.3 million raised Biophytis is announcing it has successfully completed its fundraising round for a total amount of €2.3M through capital increases with cancellation of the shareholders’ preferential subscription rights to the benefit of professional investors up to €1.9M on the one hand, and to the benefit of individual…
Biophytis launches a round of fundraising for approximately 2 million euros Biophytis announced the launch of a round of fundraising for approximately 2 million euros based on issuing new shares for professional investors, as defined below, and retail investors (through the PrimaryBid platform) (the “Operation”). Capital increases as part of a global offering comprising an…
Biophytis has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the treatment of COVID-19 Biophytis announced that it has filed for a pre-submission meeting request with the European Medicine Agency (EMA) to discuss filing for conditional Marketing Authorisation (cMA) in Europe for Sarconeos (BIO101) in the treatment of…
Biophytis strengthens its management team Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality Assurance Appointment of Nicolas Fellmann as Chief Financial Officer Fullscreen Mode
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated April 24, 2023, indicating that, based on the reported stockholders’ equity of (€1,911,000) of Biophytis as reported in its 20-F, the Company does not meet the minimum shareholders’ equity criteria…
Biophytis regains compliance with NASDAQ minimum bid price requirement Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated April 14, 2022, indicating that Biophytis has regained compliance with the Nasdaq Global Select Market minimum bid price requirement. On October 20, 2022, the Nasdaq had notified…
Biophytis Announces 2022 Financial Results and 2023 Perspectives €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101) Early Access Program (EAP) submission in…
The Combined General Meeting will be held on second call on April 17, 2023 Fullscreen Mode
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Fullscreen Mode
Positive results from the Phase 2-3 COVA study presented at the 21st ERS 2023 Lung Science Conference .Biophytis announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th…
Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-19 Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for…
Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of COVID-19 Biophytis announced that it has begun the process of early access application in France from the French National Authority for Health (HAS) for the…
Biophytis announced it is convening an Extraordinary and Ordinary Shareholders’ Meeting for March 30, 2023 Delegation to the Board of Directors to reduce the nominal value Regrouping of the company’s shares Renewal of Authorizations granted at the June 2022 AGM Stanislas Veillet, CEO of Biophytis, stated: “Following COVA study positive results, we now wishe to…
Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure, Biophytis management is inviting all of Biophytis’ stakeholders to an online event with KOL.
Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones Fullscreen Mode
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business…
Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Biophytis made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York. During this oral…
Biophytis to update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Phase 2-3 COVA study results expected in Q3 2022 Biophytis announces its CEO, Stanislas Veillet, PhD, has been hosting a presentation at the 4th Annual Longevity Therapeutics Summit in San Francisco. The Biophytis presentation entitled “Discussing the…
Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million Biophytis announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based…
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress Biophytis announced that it is giving an oral presentation on the development of Sarconeos (BIO101) for the treatment of sarcopenia at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders). This…
Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the…
Biophytis announced that it is presenting new preclinical efficacy data for its product Sarconeos (BIO101) in SMA (Spinal Muscular Atrophy) at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022. This oral presentation given by Dr. Cynthia Bézier and entitled: “COMBINATION OF BIO101 WITH ANTISENSE OLIGONUCLEOTIDE THERAPY DEMONSTRATES SYNERGISTIC BENEFICIAL EFFECTS…
Biophytis announces its participation at the BIO International Convention in San Diego from the 13th to the 16th of June Biophytis announces it will participate, represented by its CEO Stanislas Veillet and its Business Development Director Benoit Canolle, at the Biotechnology Innovation Organization (BIO) International Convention to be held in San Diego from the 13th…
Biophytis announces its audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022 Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid…
Biophytis is pleased to announce the appointment of Philippe Rousseau as Chief Financial Officer. He replaces Evelyne Nguyen who is leaving the company to pursue other projects, after having dedicated two years to its development. A strong experience in biotech and listed companies Philippe Rousseau has nearly 25 years of experience in the biotech industry…
Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program ANVISA (Brazilian Health Authority) approved Biophytis’ Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care Unit Sarconeos (BIO101) treatment will be given to a maximum of 80…
Biophytis announces the drawing of the last tranche of ORNANE under the 2020 Atlas Contract for €3 million Biophytis announces the issuance of the last 120 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €3 million under its existing convertible bond agreement with Atlas, a specialized investment fund…
Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development A Type B/End-of-Phase 2 meeting is planned with FDA (Food and Drug Administration) on January 24th, 2022,…
Biophytis obtains a new 10M€ loan structure with Kreos Capital Biophytis announces that the Company entered into a new loan structure with Kreos Capital. Stanislas Veillet, CEO of BIOPHYTIS, stated: “This transaction allows us to fund the final steps of our COVA phase 2-3 study in COVID-19, mostly for registration under Emergency Use Authorization with…
Biophytis announces US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID-19 Biophytis announces that patient recruitment in the United States, paused in May while waiting for results of the Interim Analysis 2, has restarted. The Data Monitoring Committee (DMC) had recommended in September from the Interim Analysis 2…
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021 Biophytis today announces it will present full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia at the…
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19 Biophytis today announces the recommendation by the Data Monitoring Committee (DMC) to continue the Phase 2-3 COVA study without any modification of the protocol, after the interim efficacy data were found…
Biophytis announces its management will participate and meet with investors at the following upcoming events and conferences: H. C. Wainwright 23rd Annual Global Investment ConferenceSeptember 13 to 15 – Virtual Amsterdam MidCap EventSeptember 20 to 21 – Virtual Investor Access EventSeptember 27 to 28 – Paris HealthTech Innovation DaysOctober 4 to 5 – Paris European…
SAVE THE DATE THURSAY, SEPTEMBER 30 • ROUNDTABLE 9:00-9:30 AM USA (EST) TIME SARA results will be presented and discussed, in a dedicated session, during the next ICFSR congress SARCONEOS BIO101 IN SARCOPENIA: LESSONS LEARNED FROM THE SARA PROGRAM Biophytis experts : Cendrine Tourette, PhD – Waly Dioh, PhD – Jean Mariani, with the presence…
Biophytis today announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021.
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis.
Results of the Combined General Meeting on May 10, 2021
Biophytis - Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
Biophytis - Convening of Another Combined General Meeting at a Later Date
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
Biophytis Identifies False Report Regarding COVA Study
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
Biophytis AGM meeting will take place on April 26, 2021
Biophytis Reports 2020 Full Year Results
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing
Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United-States
Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19
Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States
Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021
Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia
Biophytis Presents SARA-OBS study results at the Annual Conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)
First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
Upcoming Potential Value Generating Milestones. Read the Press Release
Biophytis is participating to: – The Geneva European Midcap digital event, December 1rst & 2 2020 – The “Anticovid” Biotech sector conference organized by the SFAF on Wednesday, December 9 – The 13th International SCWD virtual conference, December 11-13 2020
Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute with NEGMA. Read the Press Release
Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
Biophitys will participate in the following events: Mid-Cap Event :October 19 & 20th Galien Week of Innovation: Oct 26-30
First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release
Biophytis announces a € 10 million capital increase through private placement. Read the Press Release
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
Biophytis Reports H1 2020 Financial Results and Provides Business Update. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences: The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference) The HTID (Health Tech Innovation Days): October 5th & 6th, Paris Bio Europe Fall : October 26-29th (Virtual Conference)
Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release
Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release
Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release
Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA. Read the Press Release
Results of the Combined General Meeting of May 28, 2020: All ordinary and extraordinary resolutions have been adopted. Read the Press Release
Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders. Read the Press Release
Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release
Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA. Read the Press Release
Convening of another combined General Meeting at a Later Date. Read the Press Release
Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release
Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders. Read the Press Release
Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA). Read the Press Release
Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19. Read the Press Release
Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release
Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release
2019 Annual Financial Report made available. Read the Press Release
Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release
Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release
Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release
Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release
Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release
Biophytis shares trading is suspended pending a new press release. Read the Press Release
Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release
Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release
